Skip to content

Trial of high flow nasal prong (HFNP) oxygen therapy for viral bronchiolitis in children's wards of south-west Sydney.

The effect of high flow nasal prong oxygen therapy versus standard care on rate of intubation and requirements for intensive care in children with viral bronchiolitis

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611001016921
Enrollment
90
Registered
2011-09-21
Start date
2011-11-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary purpose of the study is to conduct a clinical trial on the use of HFNP therapy on infants with viral bronchiolitis requiring ventilator support and compare it with the standard care at the Campbelltown and Mt Druitt Hospitals to see effect of HFNP therapy in reducing the need for intubation and cost of transferring children to specialized children hospitals.

Interventions

High flow nasal prong therapy Children with viral bronchiolitis requiring more than 2L/min oxygen will receive treatment as per protocol A (Control) or B (Treatment) Protocol B: -Patient given HFNP providing humidified and warmed to 37 degrees. -The flow rate, set to optimise oxygen saturation, will be up to 8 L/min depending on patient comfort -Duration of HFNP will vary depending on severity of the bronchiolitis. Breaks for nasal care or mobilization will be permitted. -Other treatments such

High flow nasal prong therapy Children with viral bronchiolitis requiring more than 2L/min oxygen will receive treatment as per protocol A (Control) or B (Treatment) Protocol B: -Patient given HFNP providing humidified and warmed to 37 degrees. -The flow rate, set to optimise oxygen saturation, will be up to 8 L/min depending on patient comfort -Duration of HFNP will vary depending on severity of the bronchiolitis. Breaks for nasal care or mobilization will be permitted. -Other treatments such as drug therapy will be given according to standard protocols

Sponsors

Prof John Whitehall
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
0 to 24 Months
Healthy volunteers
No

Inclusion criteria

*Male or female *Clinical features typical of viral bronchiolitis *Clinical features and SpO2 compatible with moderate to severe bronchiolitis

Exclusion criteria

*Complications of bronchiolitis discovered before enrolment, including pneumothorax *Pneumonia plus or minus bronchiolitis *Rapid progression of illness preventing opportunity for informed consent of parents or guardians.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026